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Abstract
This study provides a review of recent publications on the physics-aspects of dosimetric accuracy in high dose rate
(HDR) brachytherapy. The discussion of accuracy is primarily concerned with uncertainties, but methods to improve
dose conformation to the prescribed intended dose distribution are also noted. The main aim of the paper is to review cur-
rent practical techniques and methods employed for HDR brachytherapy dosimetry. This includes work on the determi-
nation of dose rate fields around brachytherapy sources, the capability of treatment planning systems, the performance
of treatment units and methods to verify dose delivery. This work highlights the determinants of accuracy in HDR dosime-
try and treatment delivery and presents a selection of papers, focusing on articles from the last five years, to reflect active
areas of research and development. Apart from Monte Carlo modelling of source dosimetry, there is no clear consensus
on the optimum techniques to be used to assure dosimetric accuracy through all the processes involved in HDR brachythe -
rapy treatment. With the exception of the ESTRO mailed dosimetry service, there is little dosimetric audit activity report-
ed in the literature, when compared with external beam radiotherapy verification.
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Purpose
The need for dosimetric accuracy in external beam ra-
diotherapy is well established [1,2]. A standard requirement
of the combined uncertainties in absorbed dose delivery is
often stated as 3.5% at one standard deviation, first quot-
ed by Mijnheer [3]. Dosimetric accuracy of high dose rate
(HDR) brachytherapy may also be expected to contribute
to the achievement of clinical treatment aims, tumour con-
trol and minimised normal tissue toxicity, due to the steep-
ness of the clinical dose effect curves. Van Dyk et al. [4] de-
fined a requirement for brachytherapy treatment delivery
of 3% accuracy in dose at distances of 0.5 cm or more at any
point for any radiation source. Clinical trials also depend
upon dosimetric accuracy and consistency between par-
ticipating centres. The dosimetric challenge is particularly
difficult in brachytherapy due to small treatment dis-
tances, very high dose gradients and orders of magnitude
variation in dose deposition across volumes of interest. It
may also be reasonably claimed that dosimetric accuracy
is also required to avoid treatment errors: IAEA Safety Re-
port Series No 17 [5] “Lessons learned from accidental ex-
posures in radiotherapy” discussed 32 incidents involving
brachytherapy. ICRP 86 “Prevention of accidental exposures
to patients undergoing radiation therapy” [6] noted potential
errors in brachytherapy arising from problems with equip-
ment, calibration, treatment planning, and treatment de-
livery. ICRP 97 “Prevention of high-dose-rate brachythe rapy
accidents” [7] reported more than 500 accidents involving
HDR brachytherapy. The field of brachytherapy physics,
equipment and clinical techniques is undergoing significant
innovation and rapid modernisation, including enhanced
use of imaging, improved dosimetry and treatment plan-
ning, and patient-specific optimisation [8,9]. It is of course
es sential that the requirements for dose accuracy are con-
sidered and met in all of these developments.
The scope of ‘physics-aspects of dose accuracy’ review-
ed in this paper is illustrated in Fig. 1 and includes knowled -
ge of the dose field around the source, creation of the treat-
ment plan, performance of equipment and verification of
dose delivery. Particular emphasis is placed on reviewing
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the range of measurement techniques available that have
been applied to HDR brachytherapy. We do not include the
important uncertainties arising outside the brachytherapy
clinic, such as those at the accredited dosimetry calibration
laboratories [10]. The reader is also directed to the com-
prehensive review by DeWerd et al. [11] which addresses
uncertainties of single-source dosimetry in brachytherapy
preceding clinical use. Accuracy is defined as the level of
agreement of a measured parameter to its true value, also
the degree of correctness of a quantity. In the context of this
work, accuracy between the dose prescribed by the clini-
cian and that delivered in a patient is considered. The main
contribution is a range of uncertainties, from source
dosimetry to planning algorithm performance. However,
one may also consider how well the dose distribution can
be optimised to match the clinically intended dose distri-
bution, in terms of dose delivery accuracy. 
Of course ‘physics-aspects’ are not the only contributors
to dose delivery uncertainty in brachytherapy and indeed
the more ‘clinically’ related aspects may have more, or even
overwhelming, influence on the treatment outcome than 
the ‘physics’ aspects discussed here. The clinical consider-
ation arise from a multitude of sources [12] including clin-
ical target volume definition and contouring, user opera-
tion of equipment, human factors in applicator positioning,
internal organ motion and inter- and intra-fraction appli-
cator movement [13,14]. The imaging resource and technique
employed may also have a dramatic influence on overall 
uncertainties in dose delivery, ranging from 2D orthogonal
imaging to MRI/CT fustion [15,16]. All of the physics-
processes illustrated in Fig. 1 should be considered in terms
of dosimetric accuracy and uncertainty to ensure the high-
est quality brachytherapy treatment delivery. A number of
tools have been developed in recent years and are active-
ly being refined to address dosimetry requirements, which
may have application in multiple ways, as shown in Fig. 1,
from establishing fundamental source dosimetry in terms
of absolute dosimetry traceable to a primary standard and
dose distribution around a source to in vivo verification of
treatment delivery. 
Material and methods
A systematic review was conducted of journal articles
discussing concepts, research, and practices of dosimetry
in HDR brachytherapy published from 2002 to 2012. Med-
line and Embase databases were searched with keywords
“high dose rate”, “brachytherapy”, “dosimetry” and alter -
native forms, limited to English language. 116 articles were
found of which 84 were directly relevant for the purposes
of this review. This information was supplemented by re-
viewing reference lists and personal files. 
Review of physics-processes in HDR 
brachytherapy
Source dosimetry
A number of experimental methods have been used to
measure the dose distribution and anisotropy functions of
HDR sources. These include thermoluminescent dosimeters
[17-20], ionisation chambers [21], semiconductor diodes [18],
MOSFETS [22,23], radiochromic film [24-28] and Polymer
or Fricke gel dosimetry [29]. Theoretical Monte Carlo (MC)
calculations have also been extensively utilised [17,18,
30-35]. MC simulation [36] has now become the gold-stan-
dard accepted method for determination of dose deposition
parameters (dose rate distribution) around a brachythera-
Fig. 1. HDR brachytherapy processes, considered in this review, that influence dosimetric accuracy, with a selection of tools
reported in the literature that have been applied to assess dosimetric accuracy
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py source, expressed using parameters as reco mmend ed in
the AAPM Task Group No. 43 Report (TG-43 and TG-43 U1)
[37,38]: the dose rate constant (∧), the geometry factor G(r,θ),
the radial dose function g(r), and the 2D anisotropy func-
tion F(r,θ). The AAPM report recommends that these fac-
tors can be obtained by experiment or by MC simulation,
with the AAPM Brachytherapy Subcommittee carefully su-
pervising the process and acceptance of data in relation to
defined prerequisites [39]. As early as MC methods were
employed to evaluate the dosimetry of HDR brachythera-
py sources [40].
Validation of the MC calculated dose deposition pa-
rameters for specific HDR sources has received much at-
tention. Chandola et al. [41] have compared results of MC
codes, EGSnrc and GEANT4, alongside validation by ion-
isation chamber measurements, for the Nucletron mHDR-
v2 Ir-192 brachytherapy source, finding the two codes gave
comparable results in TG-43 dosimetric data: agreement 
of dose rate constant within 1%, radial dose function with-
in 2% up to 5 cm and within 6% up to 10 cm and 2D ani -
sotropy function within 2% for polar angles 25° < θ < 140°,
up to 6% outside this range. MC has also been used for eval-
uation of clinically relevant parameters, rather than simply
dose distribution around an isolated HDR source, such as
Sureka et al. [33] who calculated relative dose distribution
and effective transmission around shielded vaginal cylin-
ders for an Ir-192 source, using MCNP4b MC code. Lliso 
et al. [42] have successfully used GEANT4 MC code to 
determine the backscatter and electron contamination
from internal shielding in HDR skin applicators. The MC
results were verified with radiochromic EBT films at sev-
eral depths in a phantom, finding agreement within mea -
surement uncertainty.
The quality of radiochromic film has improved over the
last decade, with the active layer being more uniform and
the film being less sensitive to ambient light. A number of
recent studies have successfully used radiochromic film for
evaluation of dose distribution around HDR sources [26].
Uniyal et al. [43] have used Gafchromic EBT2 radiochromic
film and thermoluminescent dosimeters (TLD) to assess the
dose rate constant and radial dose function for the Nucle-
tron microSelectron Ir-192 source. Radiochromic film was
chosen for its higher resolution compared to other exper-
imental methods and validated against TLD results, find-
ing agreement within 3.9% for dose rate constant and 2.8%
for radial dose function. Relative to TLD dosimetry, radio -
chromic film was reported as being less expensive, easier
to use and having improved reproducibility. Aldelaijan 
et al. [24] have shown that radiochromic film may be used
in either solid water-equivalent materials or liquid water
when performing radiochromic film based dosimetry with
HDR brachytherapy sources, extending its usefulness.
The use of polymer gel dosimetry to measure dose distri-
bution around HDR brachytherapy sources was initially
complicated due to oxygen contamination and other prac-
tical issues [44]. However, new rigid materials that are sta-
ble during- and post-irradiation with linear response at low
energies and insensitive to oxygen are now available [45].
Wai et al. [46] have demonstrated the use of the solid poly -
urethane radiochromic dosimeter PRESAGETM with opti-
cal CT readout as a potential method for 3D dosimetry. Eva -
luation of the dose distribution produced by the micro -
Selectron-HDR Ir-192 source was determined using the do -
simeter and found to be in good agreement with MC
cal culation, especially at polar angles above 20°. The 3D
dosimeter was used to validate anisotropy functions 
generated with MCNP4c code, with accuracy of order 
5% achieved. However, Wai states that refinements to the
dosimetry method used are necessary before the technique
can be applied clinically. Guo et al. [47] have also evaluat-
ed the use of PRESAGETM with optical CT scanning 
(OCTOPUSTM) concluding the system provides a robust,
clinically effective and viable high-resolution relative 3D
dosimetry system for brachytherapy. Several other inves-
tigators have also contributed to the evidence for dosimetric
use of the PRESAGETM material [48,49]. 
Carrara et al. [50] used Fricke gel dosimetry to measure
the anisotropy function of an Ir-192 brachytherapy source.
A tissue equivalent phantom with Fricke gel-layer dosime-
ters was manufactured and agreement was found within
3% of the planning system data at short distances with de-
livered dose around 15 Gy, but deteriorated in more dis-
tant lower dose regions.
Antonovic et al. [51] have measured absorbed dose dis-
tributions around two Ir-192 sources with a dosimetry sys-
tem using lithium formate monohydrate (HCO2Li × H2O)
as detector material and electron paramagnetic resonance
(EPR) spectroscopy for readout. Relative standard uncer-
tainties in the experimentally determined absorbed dose was
estimated in the range 1.3 to 1.7%. Although the energy de-
pendence is less than commonly used thermoluminescent
lithium fluoride (LiF), the authors conclude the dosimeter
size needs to be reduced (from the 4.5 mm detectors used
in their study) for application to single brachytherapy source
dosimetry, where dose gradients are greater (closer than
3.0 cm from a source), in order to keep the volume averaging
correction reasonably low.
Issa et al. [52] have established the use of Ge-doped op-
tical fibres as thermoluminescence dosimeters for bra -
chytherapy applications, including comparison with calcu -
lations using DOSRZnrc MC code, finding agreement with in
3% for a Ba-133 source and 1% for a Co-60 source. 
It is important to consider the size and shape of phan-
toms used for brachytherapy source dosimetry, in both
measurement and simulations. Granero et al. [53] have de-
termined the equivalent spherical phantom size to a vari-
ety of cylinder and cube sizes for brachytherapy dosime-
try with Ir-192 and Cs-137 sources. It is noted that published
literature often employs a variety of phantom dimension
and hence different scatter conditions. 
Treatment planning
Rivard et al. [54] have comprehensively reviewed recent
developments in TPS algorithms and current research di-
rections and the reader is directed to review this publica-
tion. New model-based dose calculation algorithms are be-
ing introduced that will radically change the complexity and
potentially accuracy of brachytherapy treatment plan-
ning. In moving from the simplistic TG-43 formalism, the
limitations of liquid water dosimetry and dose distributions
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for fixed scattering conditions are being addressed, enabling
dose distributions in the presence of heterogeneities and pa-
tient scatter conditions to be evaluated with improved ac-
curacy. Advanced calculation tools, radiobiology models and
superior image guidance will shortly be available in mod-
ern TPS. In a second paper, Rivard et al. [55] considered com-
missioning techniques and quality assurance recommen-
dations of TPS utilising model-based dose calculation
algorithms. It is essential that a cautious approach is tak-
en to adopting radically new algorithms to ensure the his-
toric basis of brachytherapy prescription dosage is not aban-
doned. A joint AAPM/ESTRO/ABS working party, AAPM
Task Group 186 has been established to consider model-
based brachytherapy dosimetry techniques [56]. 
The majority of currently available, traditional bra -
chytherapy planning systems simply employ a summation
of the pre-determined dose distribution around individual
source positions based on TG43 formalism. This will lead
to some degree of uncertainty in the clinical treatment de-
livery. Chandola et al. [41] have quoted the possible mag-
nitude of error in conventional treatment planning system
dose calculations using analytical methods as ± 15 to 20%,
which may lead to overdose of organs at risk or under dose
of target volume. Chavez-Aguilera et al. [57] have provid-
ed a more conservative estimate of the potential error, by
comparing a conventional treatment planning system with
MC code and CT data, providing a result of 8% underes-
timate of the absorbed dose by the treatment planning sys-
tem, due to density and chemical composition variations.
Parsai et al. [58] have considered the effect of stainless steel
applicator tubing (Fletcher-Suit-Delclos) in cervical and en-
dometrial cancers, comparing conventional treatment 
planning system dose predictions with that calculated by
MCNP MC code, for an Ir-192 source. A reduction of dose
to ICRU Point A of at least 3% was determined when us-
ing the planning system, which did not account for the pres-
ence of the steel applicator.
Uniyal et al. [59] used Gafchromic EBT2 radiochromic film
to assess the effect of rectal air heterogeneity in Ir-192 HDR
treatment of carcinoma of the uterine cervix. Experimental
measurements using EBT2 film in a rectal phantom, veri-
fied by MC simulations, showed 12.8% dose reduction to
the closest rectal surface compared to the treatment plan-
ning system, due to lack of back scattering, whereas at the
farthest rectal surface it was 24.5% higher due to no atten-
uation. Desbiens et al. [60] have also assessed the effect of
inhomogeneities including presence of the applicator, air
pockets in the CTV and OARs and tissue heterogeneities us-
ing Geant4 MC code, with the CT data from 38 patients un-
dergoing Ir-192 gynaecologic interstitial HDR brachythe -
rapy. Maximum effect on CTV D90 was 8% and for V100 
and V150, 4% and 10%, respectively. Rectum indices reduced
by an average of 3% and urethra and bladder by less than
1%. The authors concluded taking account of heteroge -
neities has relatively small effects on dose distributions, 
however excluding air pockets and applicator volumes from
the CTV is important. Lakshminarayanan et al. [61] have ex-
plored the suitability of using point kernels for brachythe -
rapy dose calculations to take account of heterogeneities in
treatment planning and validated these against MC calcu-
lated dose distributions, finding agreement within 5% in
point doses. The authors propose brachytherapy treatment
planning with point kernel dose calculation techniques pro-
vides clinically required accuracy with rapid calculation
compared to full MC evaluations. DeMarco et al. [62] have
shown conventional brachytherapy treatment planning 
system algorithms are especially prone to calculation errors
for HDR surface applicator mould treatments with irreg-
ular surface lesions. In work comparing TG-43 calculation
algorithm with MCNPx MC code, it was shown that the rel-
ative size and shape of the bounding medium surrounding
an HDR brachytherapy source can have a significant effect
(10 to 45%) on the calculated dose distribution relative to
a reference TG-43 calculation algorithm. The changed
scatter conditions from TG-43 based planning systems to
specific patient treatment situations is comprehensively 
explored by Granero et al. [53], which is completely appli-
cable to the surface applicator situations reported above.
Zourari et al. [63] have proposed a new method for ver-
ification of the dosimetric accuracy of these advanced TPS,
utilising a virtual phantom/DICOM-protocol based qual-
ity control procedure for Ir-192 HDR brachytherapy. A set
of virtual DICOM CT image format phantoms were pre-
pared to test homogeneous and inhomogeneous perform-
ance as well as contouring, DVH calculation etc., as is com-
mon in external beam TPS. Dosimetry calculations of the
advanced planning system were compared to MC gener-
ated data with good agreement. The authors concluded that
the developed test tools provide an appropriately thorough
QC of dosimetric performance and other basic features of
both conventional and contemporary brachytherapy TPS. 
Zourari et al. [64] and Petrokokkinos et al. [65] have also con-
sidered the accuracy of a deterministic radiation transport
based brachytherapy treatment planning system (Brachyvi-
sion v8.8), validating against MCNP MC code and VIP poly-
mer gel with magnetic resonance imaging, for the cases of
single sources, multiple source dwell positions and a shield-
ed applicator. TPS and MC dose distributions were in agree-
ment within 2%, except in the penumbra of the shield where
TPS calculation errors increased (validated against meas-
urement). In all other regions agreement between TPS and
MC code was within 5% or 2 mm. The authors compared
these results to other planning systems which do not account
for shielding in applicators where dosimetry errors of 20 to
30% may be present at the edge of the unshielded segment. 
In addition to uncertainties introduced by TG-43 based
dosimetry, the accuracy of the final dose delivery in com-
parison to that intended by the prescribing doctor is also
affected by the level of optimisation that can be achieved
during the planning process. While this is properly termed
improved ‘conformality’ rather than improved ‘accuracy’,
these issues are mentioned here for completeness. The con-
ventional use of treatment planning systems for HDR bra -
chytherapy planning is a manual iterative modification 
of dwell times and/or positions until an acceptable isodose
distribution is achieved. Use of inverse planning algorithms
[66] has become common although there is understandable
reluctance to abandon completely traditional ‘loading pat-
terns’ which have been in use for many years. There have
been numerous studies evaluating modified HDR source
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loading patterns to achieve best conformation of isodoses
to the clinically identified target volume, hence improving
the accuracy of dosimetric delivery in comparison to that
intended. One early example is from Brooks et al. [67] in 
cervical cancer, in which standard plans to Manchester Point
A and conformally loaded plans prescribed to the planning
target volume were compared using the Baltas conformal
index (COIN), finding the optimised plans achieved superior
isodose distributions. Siauw et al. [68] have developed a new
approach for HDR brachytherapy planning by directly op-
timizing the dose distribution based on dosimetric criteria,
with a fast heuristic. They have demonstrated clinically ac-
ceptable performance in prostate HDR cases.
It is also necessary to check the accuracy of the treatment
plan prior to delivery in order to ensure absence of inad-
vertent errors which could affect dosimetric accuracy. 
Although manual methods are possible, it is preferable to 
automate this process, as described by Kumar et al. [69] who
developed a software tool in VC++ code for plan verifica-
tion using TG-43 parameters. The verification software and
a conventional treatment planning system were found to
agree within 3% in the majority of clinical cases. Astraham
[70] has also implemented an independent check pro-
gramme that runs on personal digital assistants (PDAs), and
Carmona et al. [71] a spreadsheet-based independent cal-
culation procedure.
Finally, crucial to the accuracy of treatment planning is
the uncertainties that may be introduced by the image-
guided techniques that are employed. Cormack [72] has re-
viewed the quality assurance issues associated with 3D 
imaging in brachytherapy. While some aspects are clearly
clinical, such as image interpretation and target delineation,
the uncertainty of applicator/source localisation and implant
reconstruction has potential for significant error if not ac-
curately undertaken.  
Equipment performance
It is essential to comprehensively commission brachyther-
apy treatment units to fully assess their performance char-
acteristics to ensure accurate dose delivery, as reported by
Palmer et al. [73]: Autoradiography of source dwell posi-
tions, video camera analysis of both source transit profiles
and dwell times, corrections for transit doses, as well as ab-
solute dosimetry of the source were all considered in the
commissioning. Many techniques have been proposed to
measure dose inaccuracies due to transit dose of the mov-
ing HDR source to the intended dwell position. Sahoo [74]
proposed a well-chamber measurement technique and Cal-
cina et al. [75] have developed a novel method using alanine-
EPR (electron paramagnetic resonance). Regularly quality
control testing of HDR treatment units is also a necessity
to ensure accurate treatment dosimetry [76-79]. Several pa-
pers are available with alternative methods to undertake ef-
ficient and comprehensive testing, for example Yewond-
wossen et al. [80] have demonstrated the use of a 2D-array
of ion chambers for brachytherapy dosimetric quality as-
surance and Devic et al. [81] have used radiochromic film
to compare delivered doses with intended treatment plans.
Accurate determination of the HDR source strength is
an obvious prerequisite for delivery of the intended dose
distribution. However, even this step requires careful at-
tention to avoid the potential for error, as reported by
Dempsey [82] in which a well-type ionisation chamber cal-
ibration coefficient contained a 2.6% error from the cali-
bration laboratory. There are several options to directly
measure the absorbed dose to water in HDR brachythera-
py to verify the source strength. Sarfehnia [83] has compared
water calorimetry, ionization chamber and radiochromic
film. Compared to water calorimetry, EBT-1 Gafchromic
film, A1SL Exradin miniature Shonka thimble chamber and
SI HDR 1000 Plus well-type chamber all agreed to within
0.8%. The overall 1 sd uncertainty was 1.9% for water
calorimetry, 1.4% for ionization chambers and 1.8% for Gaf -
chromic film. Recent development of water calorimetry-
based standards for absorbed dose to water in HDR bra -
chytherapy have simplified the fundamental dosimetry
formalism. Toni [84] and Quast et al. [85] provide reviews
of the new brachytherapy dosimetry standards. Sarfehnia
et al. 2010 [86] have reported on a water-calorimetry based
system for Ir-192 dosimetry, demonstrating absorbed dose
per air kerma strength agreement to within 0.8% with in-
dependent ionization chamber and EBT-1 Gafchromic
film reference dosimetry. DeWerd et al. [11] has undertak-
en a full uncertainty analysis of brachytherapy dosimetry,
considering each step in the dosimetry chain from standards
laboratory to clinical brachytherapy department. A com-
bined dosimetric uncertainty of < 5% (k = 1) is estimated. 
Interdepartmental or mailed quality audits are also
a valuable method of comparing dosimetric accuracy and
contributing to safety, in specific brachytherapy clinics, as
reviewed by Sibata and Gossman [87]. A brachytherapy au-
dit was conducted in The Netherlands and Belgium, re-
ported by Elfrink et al. [88], to assess accuracy of brachyther-
apy treatments, implant reconstruction and dose delivery.
A cubic phantom containing positionally well-known met-
al spheres for reconstruction tests and another cylindrical
phantom consisting of three catheters surrounding a cen-
trally positioned NE2571 ionization chamber, were sent to
33 radiotherapy centres. An intended prescribed dose to the
chamber which was compared to measurement, for HDR,
PDR and LDR systems. The average dose difference was
+0.9% (±1.3%, 1sd) for 21 HDR units and the average ap-
plicator reconstruction accuracy was –0.07 mm (±0.4 mm,
1 sd). A dosimetric intercomparison of brachytherapy treat-
ment units in 9 radiotherapy centres in Ireland, Scotland and
the North of England was reported by Heeney et al. [89].
A phantom was used to perform in-air measurements of
source strength with a standard Farmer-type ionisation
chamber. 5 HDR units were surveyed, with the difference
between locally measured to audit measured source
strengths of between +1.5% to –0.9%. The quoted mean rel-
ative combined uncertainty was 1.3%. 
A quality control audit based on a mailed TLD system
(LiF powder type DTL 937, Philitech) has been developed
by the BRAPHYQS Physics Network and the EQUAL-ES-
TRO laboratory, as reported by Roue et al. [90]. The system
measures the absorbed dose to water in the vicinity of an
HDR or PDR source, at a uniform dose location at the cen-
tre of three source cat heters housed in a purpose designed
PMMA phantom. The aim is to compare the dose to water
measured with the TLD and the dose calculated by the clin-
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ical TPS, with a total uncertainty budget of 3.3%. At the time
of publication (2007),  11 centres had undertaken the audit
and one result was found outside of tolerance due partial-
ly to an incorrect ca libration coefficient detected. The au-
thors conclude that such external audit can be an efficient
QC method complementary to internal quality control as
it can reveal some errors which are not observable by oth-
er means. 
An audit of source strength determination for HDR
brachytherapy was conducted in 14 Swedish centres by
Carlsson Tedgren et al. [91]. Values of reference air kerma
rate (RAKR) were compared from the external audit, hos-
pitals’ measurements as well as vendors certificates, and 
all agreed within the uncertainty limits stated by the ven-
dors. The use of robust well-type ionisation chambers was
thought to contribute to the high levels of agreement. Auster-
litz et al. [92] have proposed a Fricke dosimetry system for
clinical HDR quality control audits via mail distribution. 
The prototype system consisted of a water phantom with
the HDR source positioned at the centre of a spherical bal-
loon filled with Fricke solution. The authors confirmed suit-
ability of the system for assessment of source strength, de-
cay and treatment planning parameters. Ochoa et al. [93]
have reported on a phantom design for the verification of
the dose calculated by the treatment planning system, us-
ing powder TLD capsules. An in-air measurement of source
strength and in-water verification of the dose calculation al-
gorithm are employed. The system was mailed to seven ra-
diotherapy centres in Brazil, with comparisons between
phantom measurement, well-type ionisation chamber and
source specification certificate agreeing within 3%. The au-
thors conclude the phantom demonstrated its usefulness to
verify the source strength and consistency of TPS to calculate
the absorbed dose delivered to the patient, as part of a Na-
tional Dosimetry Quality Assurance Program in Brazil. This
work followed an earlier publication by de Almeida et al.
[94] in which a pilot HDR dosimetry audit was conducted. 
Dose delivery verification
Verification of dosimetric accuracy of the delivered treat-
ment plan may ideally be assessed in vivo to record the ac-
tual dose delivered within the patient. However, there are
a number of uncertainties with this approach, not least 
positional dependence of the dosimeter within the patient.
An alternative, or perhaps additional, process is the prior
verification of intended treatment delivery in a phantom.
Qi et al. [95] have evaluated the use of a MOSFET dosime-
try system within a custom made phantom to verify HDR
brachytherapy plan delivery. Deviations between measured
doses and treatment planning system calculated doses were
all within 5% for the plans considered.
The optimum detector to confirm in vivo dosimetric ac-
curacy in HDR brachytherapy has not yet been established.
A number of systems have been used and are being de-
veloped including passive integrating TLDs and active meth-
ods based on MOSFETS, diodes, optical fibre-coupled or-
ganic scintillators or doped silica glass. Lambert et al. [96]
compared a scintillation detector (BrachyFOD) with a di-
amond detector, MOSFET and LiF TLD in the presence of
an Ir-192 source. The diamond detector was found to be the
most accurate, but had a large physical size, TLDs were not
favoured due to inability of real-time readings and had
depth dependent sensitivity, MOSFETs used in the study
were subject to large errors at distances greater than
50 mm from the source. The authors concluded a scintilla-
tion detector could have the most favourable combination
of characteristics for in vivo dosimetric verification in HDR
brachytherapy. 
The use of thermoluminescent dosimetry (TLD) is a tra-
ditional method for external beam verification and has also
frequently been applied for in vivo use in HDR brachythe -
rapy. Das et al. [97] reported on the use of LiF:Mg,Ti TLD
rods of 1 mm diameter, with up to 11 detectors positioned
every 16 mm separated by radio-opaque markers, in cat -
heters within the urethra and rectum of prostate cancer pa-
tients. Hsu et al. [98] compared the use of a radiophotolu-
minescent glass dosimeter (RPLGD) to a traditional
thermoluminescent dosimeter for the dose verification of
prostate HDR brachytherapy. The authors concluded the
RPLGD demonstrated good repeatability, stability and small
effective size, and showed promise as a reliable dosimeter
for in vivo dosimetry with clinically acceptable accuracy.
The use of remote optical fibre dosimetry in brachythe -
rapy [99] has received some attention in brachytherapy. 
Andersen et al. [100] characterized a fibre-coupled Al2O3:C
luminescence dosimetry system for online in vivo dose
measurement with an Ir-192 brachytherapy source, to fa-
cilitate prevention and identification of dose delivery errors.
The system uses both radioluminescence (RL) and optically
stimulated luminescence (OSL) from aluminium oxide crys-
tals attached to optical fibre cables. The authors found the
system was adequate for in vivo brachytherapy dosimetry. 
A fibre optic dosimetry system was also developed by 
Suchowerska et al. [101] to measure urethral and rectal wall
doses in HDR prostate patients. In the study of 25 patients,
the dosimetry system indicated a maximum departure of
9% from the calculated dose in the urethra. The authors in-
dicate knowledge of the actual dose delivered could be used
to correlate to toxicity, or as a warning of potential over or
under dose. Kertzscher et al. [102] have also investigated the
use of a real-time fibre-coupled carbon doped aluminium
oxide (Al2O3:C) crystal dosimeter for in vivo dosimetry de-
tection of imposed treatment errors in phantom studies, for
gynaecological and prostate treatment plans. Interchanged
guide tubes and 2 to 20 mm source displacements were mo -
nitored with the detector in the tumour region. It was
found applicator displacements greater or equal to 5 mm
and interchanged guide tube errors could be detected by
real-time dosimetry. Therriault-Proulx et al. [103] have also
used a plastic scintillation detector (PSD) coupled to a plas-
tic optical fibre to perform in-phantom dosimetry during
Ir-192 HDR brachytherapy treatments. Prostate plan HDR
treatments were delivered to the PSD in water, comparing
the measured values to treatment planning system calcu-
lations. The PSD is designed for verification of dose in rec-
tum and urethra. An intentional 5 mm displacement of the
source was detected by the PSD in over 78% of delivered
plans. The study also demonstrated the need to implement
a stem effect removal technique for the PSD signal, which
the author had previously reported in more detail [104]. 
The authors state the system has the potential for various
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online verifications of treatment delivery quality in HDR
brachytherapy.
There have been a number of publications assessing the
possibility of using metal oxide semiconductor field effect
transistor detectors (MOSFETs) as in vivo dosimeters [105].
Haughey et al. [106] assessed the suitability of linear array
MOSFETs as in vivo dosimeters to measure rectal dose in
HDR cervix brachytherapy treatments. MOSFET dosime-
ters are attractive due to their small sensitive volume and
direct readout. CT scans were obtained with the MOSFETs
inserted into the patients’ rectum and measured rectal 
doses during treatment were compared with point doses
calculated by the treatment planning system (TPS). For
prostate patients, only 33% of measured doses agreed with
the TPS within 10% and for cervix, 42% agreed within 10%.
Due to the many uncertainties associated with MOSFETs
including calibration drift, angular dependence and the in-
ability to know their exact position at the time of treatment,
Haughey et al. considered them to be unsuitable for rectal
in vivo dosimetry in HDR brachytherapy. Reniers et al. [107]
also evaluated the performance of MOSFET detectors for
in vivo dosimetry to verify correct dose delivery in gynae -
cological HDR brachytherapy. It was acknowledged that
information on dosimeter position with respect to the source
is paramount to the interpretation of in vivo measurements
due to high dose gradients that are present. 
The RADPOS system (Best Medical, Canada) consists of
a MOSFET do si meter physically coupled to a position-sens-
ing probe, which deduces its 3D position in static magnetic
fields generated by a transmitter, shown to be accurate with-
in 0.5 to 1.0 mm. MC code was used to derive the photon
energy spectrum at the known distance from the source,
to interpret the MOSFET reading. The authors concluded 
the system showed promise as an in vivo dosimetry sys-
temfor HDR brachytherapy. Able et al. [18] have also used
a MOSFET dosimetry system as the detectors in a prostate
phantom for HDR treatment. The purpose of the work was
to assess the application of statistical process control
(SPC) as a quality control method to ensure the treatment
was delivered with minimal variation. CT guidance was
used for positioning of detectors, exposed to treatments de-
livered accurately and with induced errors. SPC method-
ology was shown to be a valuable approach with further
work required on determining the most effective posi-
tioning of the detec tors. Anton et al. (2009) [109] have con-
ducted a prostate phantom study to demonstrate the po-
tential of alanine/ESR as an in vivo dosimeter with an Ir-192
source. The uncertainty of measurement within a Foley
catheter for dose measurements within the urethra was es-
timated to be 3.6%, concluding this to be suitable for clin-
ical in vivo measurements. Holly et al. [110] used a cone-
beam CT imaging technique to verify the positioning of
HDR applicators prior to treatment delivery, in prostate
brachytherapy. The mean internal displacement of the
catheters was 11 mm, resulting in a decrease in mean vol-
ume receiving 100% of prescription dose (V100) from
planned 97.6% to 77.3% (p < 0.001). Each 1 cm of catheter
displacement resulted in a decrease of 20% in V100 and 
a reduction in the mean dose to 90% of the prostate (D90)
of 36%. The study showed internal displacement of HDR
catheters for prostate treatment is common, but can be part-
ly corrected if detected. These results are similar to the work
of Foster et al. [111] who also evaluated the impact of in-
terfraction catheter movement on dosimetry in prostate
HDR brachytherapy using CT. A mean displacement of
5.1 mm was recorded, resulting in prostate V100 reduction
from 93.8% to 76.2%, considered significant by the authors
and required re-optimisation before the second treat-
ment. Meiln Bermejo et al. [112] have developed the use of
Gafchromic EBT2 film to confirm the correct dose delivery
to the surface of the skin in skin cancer treatments. A sig-
nificant challenge in dosimetry is the surface-dose deter-
mination because of its experimental complexity. Measu -
rements with EBT2 were shown to be a suitable method for
QA purposes in HDR brachytherapy. Hassouna et al. [113]
have shown that in vivo dosimetry using diodes can pro-
vide appropriate quality control of HDR brachytherapy
treatments in cervix cancer. Following calibration and
a phantom study to estimate the reproducibility (0.5%) and
uncertainty (1.9%) of the in vivo dosimetry system, a pro -
spective study using the detectors in 32 intracavitary bra -
chytherapy implants was conducted. 48% of rectal diode
measurements and 46% of bladder diode measurements
were more than 10% different from TPS expected dose. 
The cause was likely difficulties in position verification in
high dose gradients.
The method of interpretation of in vivo dosimetry results
must be considered alongside the development of dosime-
try systems themselves, in order to interpret the accuracy
of treatment delivery and take clinical decision based on
measurement results. Toye et al. [114] have developed an
in vivo dosimetry based investigative action level relevant
for a corrective protocol for HDR brachytherapy prostate
boost treatment. This was based on urethra and rectum ther-
moluminescent (TLD) dosimetry in 56 patients. An initial
investigative level of 20% difference between measurement
and treatment planning system was established, corre-
sponding to 1/3 of patients. 
Discussion 
A review of recent published work concerned with im-
proving or verifying the dosimetric accuracy of HDR
brachytherapy treatments has been presented. A wide range
of tools are currently being employed to achieve this aim,
with no consensus on the optimum method for each element
of the process, except in the determination of HDR source
dose rate distribution where MC methods prevail. Even for
these calculations, the majority of investigators use an ad-
ditional experimental technique for validation of calcula-
tion results, which may include point dose TLDs, 2D ra-
diochromic film and 3D gel/plastic dosimeters. The benefits
of particular detector systems are related not only to their
physical properties, such as size, dose resolution, respon -
se, uncertainty, but also to practical usability in brachythe -
rapy. For verification of MC-derived dose distributions
around individual source models, a full-3D gel dosimeter
may be desirable, but is impractical for routine quality con-
trol checks where radiochromic film or ionisation chambers
provide more immediate results. 
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The lack of correction for tissue or applicator inhomo-
geneities and patient-specific scattering conditions in
brachytherapy treatment planning systems is well known,
but the effect on dose distributions and clinical implications
has less agreement; with estimates ranging from 3 to 25%
in different conditions. It is likely that model-based advanced
planning systems will become more widespread in the near
future to reduce this uncertainty. There is also scope to im-
prove the use of treatment planning systems to achieve the
desired dose distribution, development of new applicators
and a gradual move away from traditional brachytherapy
loading systems. Equipment performance should not be for-
gotten as an essential step in ensuring dosimetric accura-
cy, both in initial comprehensive commissioning and reg-
ular quality control testing. There appears to be a lack of
interdepartmental audits, clinical trials quality assurance,
or routine external audit testing for HDR brachytherapy in
the published literature. The majority of publications are re-
lated to Ir-192, this being the most common isotope in clin-
ical use, with a lack of work for newer HDR sources such
as Co-60. In vivo verification of dose delivery has received
much attention, with investigators using a number of
tools including TLD, MOSFET, semiconductor diodes, re-
mote optical fibre dosimetry, alanine and radiochromic film.
However, accurately verifying the precise location of the de-
tectors in the steep dose gradients involved in brachyther-
apy treatment has restricted the quality that has been
achieved with in vivo measurements and relatively high un-
certainties remain. Attention may be better directed towards
a combination of verification of the equipment performance
during treatment with improved image-guidance to ensure
correct relative locations of applicators and internal struc-
tures. Imaging verification of brachytherapy delivery re-
quires further development. There has been some work 
confirming applicator position, but only limited studies on
in vivo assessment of the correlation of internal organ mo-
tion with respect to applicators, namely in prostate HDR.
The correct identification, reconstruction and position of 
applicators are critical to the accuracy of brachytherapy. 
The extensive development and adoption of advanced im-
age-guidance for external beam radiotherapy may be re-
peated for brachytherapy in the near future. 
As the complexity of brachytherapy delivery increases,
there is also scope to develop pre-treatment delivery
checks, as is common for external beam intensity-modulated
radiotherapy. A required nominal overall accuracy for bra -
chytherapy dose delivery of 3% is sensible [4]. However, in
assessing the accuracy of the delivered dose distribution
compared to the plan, there is a lack of an accepted definition
of quality. The application of gamma-type assessments 
of intended compared to delivered dose distributions
would be of value for brachytherapy. 
It is difficult to specify and quantify the current achiev-
able accuracy in HDR brachytherapy treatments. The ac-
curacy of physical dose delivery, including source strength
calibration, is expected to be better than 3%. Treatment plan-
ning system accuracy, using TG-43 approach, is generally
within 2% of measured or MC calculated doses, although
uncertainties increase in the presence of inhomogeneities.
Other determinants of accuracy such as variations in treat-
ment equipment performance have not been comprehen-
sively evaluated within HDR brachytherapy treatments. 
The uncertainties of greatest magnitude in brachytherapy
treatment are currently likely to be associated with ‘clini-
cal’ aspects of target volume definition, applicator position
and movement and the effect of internal organ movement.
In terms of overall dosimetric accuracy of brachythera-
py treatments, it may be useful to consider quality system
approaches, to target research work in those areas with 
the largest current uncertainty or indeed where there is 
the greatest potential for treatment error. Swamidas et al.
[115] have evaluated the safety of intracavitary brachythe -
rapy using failure mode and effects analysis (FMEA) ac-
cording to a method being used by the American Asso ciation
of Physicists in Medicine (AAPM) Task Group No 100, as-
signing risk probability to all process elements. Similarly,
Thomadsen et al. [12] have applied formal risk analysis tech-
niques to dosimetric accuracy of brachytherapy. 
Conclusions
Assuring the dosimetric accuracy of HDR brachythera-
py, reducing uncertainties and improving dose delivery op-
timisation, are all areas where significant development and
research work is being undertaken, with many varied tools
being employed for both calculation and experimental in-
vestigation. In ‘source dosimetry’, MC techniques are well
established and TLD, radiochromic film, as well as gel
dosimeters have all been used to provide verification of cal-
culations. However, there is often a lack of consideration
of the size and shape of phantoms and scatter conditions
used in this work. In ‘treatment planning’, new model-based
dose calculation algorithms will revolutionise the uncertainty
associated with current TG-43 based techniques in the pres-
ence of inhomogeneities and differing scatter conditions. 
Further work is required to quantify the extent of dose dis-
tribution differences that will occur in typical treatment sit-
uations with the new TPS algorithms and indeed the
magnitude of current TG-43 uncertainties. In ‘equipment
performance’, guidance exists on local quality control
practices, but there is a lack of quality audits when compared
to similar activity in external beam radiotherapy. Source
strength measurements are also the subject of much current
research and development attention. In ‘dose delivery ver-
ification’, techniques for reliable in vivo dose measurement
have not been practically realised and therefore are not in
widespread use. Further development is required in com-
bination with improved image-guidance of brachytherapy.
The development of routine methods for the accurate de-
termination of applicator location, target and organs at risk
is required. 
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